The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain
Study sponsor: Okyo Pharma Ltd · OKYO
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-04-30Actual
Enrollment · participants18Actual
Source updated2025-08-15Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.